Simply defined as an extension of the benefit of protection from immunization in those immunized to those unimmunized in a community, herd effect was key to the success of Prevnar in North America.

While Pfizer’s earlier Prevnar 13 and Prevnar 10 have made a dent in the global burden of invasive pneumococcal disease, the bacterial infection remains a threat. According to 2021 estimates ...

A key factor fueling the growth of the Prevnar market is the increasing prevalence of pneumococcal diseases. Today, pneumococcal diseases are among the common infections caused by streptococcus ...